Overexpression of stromelysin-3, BM-40/SPARC, and MET genes in human esophageal carcinoma: Implications for prognosis

Clinical Cancer Research

Volumn 4, Issue 6, 1998, Pages 1375-1382

  Porte, Henri ^a,b   Triboulet, Jean Pierre ^b   Kotelevets, Larissa ^a   Carrat, Fabrice ^a   Prévot, Sophie ^a   Nordlinger, Bernard ^a   DiGioia, Yolande ^a   Wurtz, Alain ^b   Comoglio, Paolo ^c   Gespach, Christian ^a   Chastre, Eric ^a  

^a HÔPITAL SAINT ANTOINE   (France)

^b LILLE UNIVERSITY HOSPITAL   (France)

^c UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

METALLOPROTEINASE; OSTEONECTIN; STROMELYSIN;

ADULT; AGED; ANGIOGENESIS; ARTICLE; BASEMENT MEMBRANE; CANCER INVASION; CANCER STAGING; CANCER SURVIVAL; CELL COMPARTMENTALIZATION; CLINICAL ARTICLE; COMPLEX FORMATION; ESOPHAGUS CARCINOMA; EXTRACELLULAR MATRIX; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; TUMOR VOLUME;

ADENOCARCINOMA; ADULT; AGED; CARCINOMA, SQUAMOUS CELL; DISEASE-FREE SURVIVAL; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPHATIC METASTASIS; MATRIX METALLOPROTEINASE 11; METALLOENDOPEPTIDASES; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OSTEONECTIN; POLYMERASE CHAIN REACTION; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-MET; SURVIVAL RATE; TIME FACTORS;

EID: 18244422909     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (62)

1. Mannell, A., and Becker, P. J. Evaluation of the results of oesophagectomy for oesophageal cancer. Br. J. Surg., 78: 36-40, 1991.
2. Sagar, P. M., Gauperaa, T., Sue-Ling, H. S., McMahon, M. J., and Johnston, D. An audit of the treatment of cancer of the esophagus. Gut, 35: 941-945, 1994.
3. Schattenkerk, M. E., Obertop, H., Mud, H. J., Eijkenboom, W. M. H., Van Andel, J. G., and Van Houten, H. Survival after resection for carcinoma of the oesophagus. Br. J. Surg., 74: 165-168, 1987.
4. Sugimachi, K., Matsuoka, H., Ohno, S., Mori, M., and Kuwano, H. Multivariate approach for assessing the prognosis of clinical oesophageal carcinoma. Br. J. Surg., 75: 1115-1118, 1988.
5. Matsubara, T., Ueda, M., and Nadajima, T. Preoperative assessment of lymph nodes in the prediction of disease spread and outcome in cancer of the thoracic oesophagus. Br. J. Surg., 82: 356-369, 1995.
6. Roder, J. D., Busch, R., Stein, H. J., Fink, U., and Siewert, J. R. Ratio of invaded to removed lymph nodes as a predictor of survival in squamous cell carcinoma of the oesophagus. Br. J. Surg., 81: 410-413, 1994.
7. Liotta, L. A., Steeg, P. S., and Stettler-Stevenson, W. G. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell, 64: 327-336, 1991.
8. Vassalli, J. D., and Pepper, M. S. Membrane proteases in focus. Nature (Lond.), 370: 14-15, 1994.
9. Hollstein, M., Sidransky, D., Vogelstein, B., and Harris, C. C. p53 mutations in human cancers. Science (Washington DC), 253: 49-53, 1991.
10. Montesano, R., Hollstein, M., and Hainaut, P. Genetic alterations in esophageal cancer and their relevance to etiology and pathogenesis: a review. Int. J. Cancer, 69: 225-235, 1996.
11. Meltzer, S. J. The molecular biology of esophageal carcinoma. Recent Results Cancer Res., 142: 1-8, 1996.
12. Kumble, S., Omary, M. B., Cartwright, C. A., and Triadafilopoulos, G. Src activation in malignant and premalignant epithelia of Barrett's esophagus. Gastroenterology, 112: 348-356, 1997.
13. Matrisian, L. M. The matrix-degrading metalloproteinases. BioEssays, 14: 455-463, 1992.
14. Basset, P., Bellocq, J. P., Wolf, C., Stoll, I., Hutin, P., Limacher, J. M., Podhajcer, O. L., Chenard, M. P., Rio, M. C., and Chambon, P. A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas. Nature (Lond.), 348: 699-704, 1990.
15. Porte, H., Chastre, E., Prévot, S., Nordlinger, B., Empereur, S., Basset, P., Chambon, P., and Gespach, C. Neoplastic progression of human colorectal cancer is associated with overexpression of the stromelysin-3 and BM-40/SPARC genes. Int. J. Cancer, 64: 70-75, 1995.
16. Anderson, I. C., Sugarbaker, D. J., Ganju, R. K., Tsarwhas, D. G., Richards, W. G., Sunday, M., Kobzik, L., and Shipp, M. A. Stromelysin-3 is overexpressed by stromal elements in primary non-small cell lung cancers and regulated by retinoic acid in pulmonary fibroblasts. Cancer Res., 55: 4120-4126, 1995.
17. Muller, D., Wolf, C., Abecassis, J., Millon, R., Engelmann, A., Bronner, G., Rouyer, N., Rio, M. C., Eber, M., METhlin, G., Chambon, P., and Basset, P. Increased stromelysin-3 gene expression is associated with increased local invasiveness in head and neck squamous cell carcinomas. Cancer Res., 53: 165-169, 1993.
18. Mjamudar, G., Nelson, B. R., Jensen, T. C., Voorhees, J. J., and Johnson, T. M. Increased expression of stromelysin-3 in basal cell carcinomas. Mol. Carcinog. (Lond.), 9: 17-23, 1994.
19. Wolf, C., Chenard, M. P., Durand de Grossouvre, P., Bellocq, J. P., Chambon, P., and Basset, P. Breast cancer-associated stromelysin-3 gene is expressed in basal cell carcinoma and during cutaneous wound healing. J. Invest. Dermatol., 99: 870-872, 1992.
20. Lefebvre, O., Regnier, C., Chenard, M. P., Wendling, C., Chambon, P., Basset, P., and Rio, M. C. Developmental expression of mouse stromelysin-3 mRNA. Development (Camb.), 121: 947-955, 1995.
21. Sage, E. H. Terms of attachment: SPARC and tumorigenesis. Nat. Med., 3: 144-146, 1997.
22. Bellahcene, A., and Castronovo, V. Increased expression of osteonectin and osteopontin, two bone matrix proteins in human breast cancer. Am. J. Pathol., 146: 95-100, 1995.
23. Ledda, M. F., Adris, S., Bravo, A. L., Kairiyama, C., Bover, L., Chernoajovsky, Y., Mordoh, J., and Podhajcer, O. L. Suppression of SPARC expression by antisense RNA abrogates the tumorigenicity of human melanoma cells. Nat. Med., 3: 171-176, 1997.
24. Ledda, F., Bravo, A., Adris, S., Bover, L., Mordoh, J., and Podhajcer, O. L. The expression of the secreted protein acidic and rich in cysteine (SPARC) is associated with the neoplastic progression of human melanoma. J. Invest. Dermatol., 108: 210-214, 1997.
25. Lane, T. F., Iruela-Arispe, M. L., and Sage, E. H. Regulation of gene expression by SPARC during angiogenesis in vitro: changes in fibronectin, thrombospondin-1, and plasminogen activator inhibitor. J. Biol. Chem., 267: 16736-16745, 1992.
26. Tremble, P. M., Lane, T. F., Sage, E. H., and Werb, Z. SPARC, a secreted protein associated with morphogenesis and tissue remodeling, induces expression of metalloproteinases in fibroblasts through a novel extracellular matrix-dependent pathway. J. Cell Biol., 121: 1433-1444, 1993.
27. Funk, S. E., and Sage, E. H. Differential effects of SPARC and cationic SPARC peptides on DNA synthesis by endothelial cells and fibroblasts. J. Cell. Physiol., 154: 53-64, 1993.
28. 2+-binding EF-hand sequence. J. Cell. Biochem., 57: 127-140, 1995.
29. Comoglio, P. M., and Boccaccio, C. The HGF receptor family: unconventional signal transducers for invasive cell growth. Genes Cells, I: 347-354, 1996.
30. Weidner, K. M., Behrens, J., Wandekerckhove, J., and Birchmeier, W. Scatter factor: molecular characteristics and effect on the invasiveness of epithelial Cells. J. Cell Biol., 111: 2097-2108, 1990.
31. Giordano, S., Zhen, Z., Medico, E., Gaudino, G., Galimi, F., and Comoglio, P. M. Transfer of the motogenic and invasive response to scatter factor/hepatocyte growth factor by transfection of human MET oncogene. Proc. Natl. Acad. Sci. USA, 90: 649-653, 1993.
32. Matsumoto, K., Matsumoto, K., Nakamura, T., and Kramer, R. H. Hepatocyte growth factor/scatter factor induces tyrosine phosphorylation of focal adhesion kinase (p125 FAK) and promotes migration and invasion by oral squamous cell carcinoma cells. J. Biol. Chem., 269: 31807-31813, 1994.
33. Naldini, L., Vigna, E., Ferracini, R., Longati, P., Gandino, L., Prat, M., and Comoglio, P. M. The tyrosine kinase encoded by the MET proto-oncogene is activated by autophosphorylation. Mol. Cell. Biol., 11: 1793-1803, 1991.
34. Di Renzo, M. F., Narsimhan, R., Olivero, M., Bretti, S., Giordano, S., Medico, E., Gaglia, P., Zara, P., and Comoglio, P. M. Expression of the met/HGF receptor in normal and neoplastic human tissues. Oncogene, 6: 1997-2003, 1991.
35. Di Renzo, M. F., Olivero, M., Giacomini, A., Porte, H., Chastre, E., Mirossay, L., Nordlinger, B., Bretti, S., Bottardi, S., Giordano, S., Plebani, M., Gespach, C., and Comoglio, P. M. Overexpression and amplification of the MET/HGF receptor gene during the progression of colorectal cancer. Clin. Cancer Res., 1: 147-154, 1995.
36. Lankat-Buttgereit, B., Mann, K., Deutzmann, R., Timpl, R., and Krieg, T. Cloning and complete amino acid sequences of human and murine basement membrane protein BM-40 (SPARC, osteonectin). FEBS Lett., 236: 352-356, 1988.
37. Empereur, S., Djelloul, S., Di Giola, Y., Bruyneel, E., Mareel, M., Van Hengel, J., Van Roy, F., Comoglio, P. M., Courtneidge, S., Parakewa, C., Chastre, E., and Gespach, C. Progression of familial adenomatous polyposis (fap) colonie cells after transfer of the SRC or polyoma middle T oncogenes: cooperation between src and HGF/MET in invasion. Br. J. Cancer, 75: 241-250, 1997.
38. Santavicca, M., Noel, A., Chenard, M. P., Lutz, Y., Stoll, I., Segain, J. P., Rouyer, N., Rio, M. C., Wolf, C., Bellocq, J. P., and Basset, P. Characterization of monoclonal antibodies against stromelysin-3 and their use to evaluate stromelysin-3 levels in breast carcinoma by semiquantitative immunohistochemistry. Int. J. Cancer, 64: 336-341, 1995.
39. Hartmann, G., Naldini, L., Weidner, K. M., Sachs, M., Vigna, E., Comoglio, P. M., and Birchmeier, W. A functional domain in the heavy chain of scatter factor/hepatocyte growth factor binds the c-MET receptor and induces cell dissociation but not mitogenesis. Proc. Natl. Acad. Sci. USA, 89: 11474-11578, 1992.
40. Cioce, V., Csaky, K. G., Chan, A. M. L., Bottaro, D. P., Taylor, W. G., Jensen, R., Aaronson, S. A., and Rubin, J. S. Hepatocyte growth factor (HGF)/NK1 is a naturally occurring HGF/scatter factor variant with partial agonist/antagonist activity. J. Biol. Chem., 271: 13110-13115, 1996.
41. Lane, T. F., Iruela-Arispe, M. L., Johnson, R. S., and Sage, E. H. SPARC is a source of copper-binding peptides that stimulate angiogenesis. J. Cell. Biol., 125: 929-943, 1994.
42. Fontanini, G., Vignati, S., Bigini, D., Mussi, A., Lucchi, M., Chine, S., Angeletti, C. A., and Bevilacqua, G. Recurrence and death in non-small cell lung carcinomas: a prognostic model using pathological parameters, microvessel count, and gene protein products. Clin. Cancer Res., 2: 1067-1075, 1996.
43. Schmidt, L., Duh, F. M., Chen, F., Kishida, T., Glenn, G., Choyke, P., Scherer, S. W., Zhuang, Z., Lubensky, I., Dean, M., Allikmets, R., Chidambaram, A., Bergerheim, U. R., Feltis, J. T., Casadevall, C., Zamarron, A., Bernues, M., Richard, S., Lips, C. J. M., Walther, M. C. M., Tsui, L. P., Geil, L., Orcutt, M. L., Stackhouse, T., Lipan, J., Slife, L., Brauch, H., Decker, J., Niehans, G., Hughson, M. D., Moch, H., Storkel, S., Lerman, M. I., Linehan, W. M., and Zbar, B. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat. Genet., 16: 68-73, 1997.
44. Gambarotta, G., Boccaccio, C., Giodano, S., Ando, M., Stella, M. C., and Comoglio, P. M. ets up-regulates MET transcription. Oncogene, 13: 1911-1917, 1996.
45. Ivan, M., Bond, J. A., Prat, M., Comoglio, P. M., and Wynford-Thomas, D. Activated ras and ret oncogenes induce over-expression of c-met (hepatocyte growth factor receptor) in human thyroid epithelial cells. Oncogene, 14: 2417-2423, 1997.
46. Takada, N., Yano, Y., Matsuda, T., Otani, S., Osugi, H., Higashino, M., Kinoshita, H., and Fukushima, S. Expression of immunoreactive human hepatocyte growth factor in human esophageal squamous cell carcinomas. Cancer Lett., 97: 145-148, 1995.
47. Miyazawa, K., Shimomura, T., and Kitamura, N. Activation of hepatocyte growth factor in the injured tissues is mediated by hepatocyte growth factor activator. J. Biol. Chem., 271: 3615-3618, 1996.
48. Naldini, L., Tamagnone, L., Vigna, E., Sachs, M., Hartmann, G., Birchmeier, W., Daikuhara, Y., Tsubouchi, H., Blasi, F., and Comoglio, P. M. Extracellular proteolytic cleavage by urokinase is required for activation of hepatocyte growth factor/scatter factor. EMBO J., 11: 4825-4833, 1992.
49. Shimomura, T., Denda, K., Kitamura, A., Kawaguchi, T., Kito, M., Kondo, J., Kagaya, S., Qin, L., Takata, H., Miyazawa, K., and Kitamura, N. Hepatocyte growth factor activator inhibitor, a novel Kunitz-type serine protease inhibitor. J. Biol. Chem., 272: 6376-6371, 1997.
50. Bussolino, F., Di Renzo, M. F., Ziche, M., Biochetto, E., Olivero, M., Naldini, L., Gaudino, G., Tamagnone, L., Coffer, A., and Comoglio, P. M. Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth. J. Cell. Biol., 119: 629-641, 1992.
51. Chenard, M. P., O'Siorain, L., Shering, S., Rouyer, N., Lutz, Y., Wolf, C., Basset, P., Bellocq, J. P., and Duffy, M. J. High levels of stromelysin-3 correlate with poor prognosis in patients with breast carcinoma. Int. J. Cancer, 69: 448-451, 1996.
52. Engel, G., Helselmeyer, K., Auer, G., Backdahl, M., Eriksson, E., and Linder, S. Correlation between stromelysin-3 mRNA level and outcome of human breast cancer. Int. J. Cancer, 58: 830-835, 1994.
53. Hahnel, E., Harvey, J. M., Joyce, R., Robbins, P. D., Sterrett, G. F., and Hahnel, R. Stromelysin-3 expression in breast cancer biopsies: clinico-pathological correlations. Int. J. Cancer, 55: 771-774, 1993.
54. Pei, D., Majmudar, G., and Weiss, S. J. Hydrolytic inactivation of a breast carcinoma cell-derived serpin by human stromelysin-3. J. Biol. Chem., 269: 25849-25855, 1994.
55. Desrochers, P. E., Jeffrey, J. J., and Weiss, S. J. Interstitial collagenase (matrix metalloproteinase-1) expresses serpinase activity. J. Clin. Invest., 87: 2258-2265, 1991.
56. Mari, B. P., Anderson, I. C., Mari, S. E., Ning, Y. Y., Lutz, Y., Kobzik, L., and Shipp, M. A. Stromelysin-3 is induced in tumor/stroma cocultures and inactivated via a tumor-specific and basic fibroblast growth factor-dependent mechanism. J. Biol. Chem., 273: 618-626, 1998.
57. Noel, A. C., Lefebvre, O., Maquoi, E., Vanhoorde, L., Chenard, M. P., Mareel, M., Foidart, J. M., Basset, P., and Rio, M. C. Stromelysin-3 expression promotes tumor take in nude mice. J. Clin. Invest., 97: 1924-1930, 1996.
58. Manes, S., Mira, E., del Mar Barbacid, M., Ciprés, A., Fernandez-Resa, P., Buesa, J. M., Mérida, I., Aracil, M., Marquez, G., and Martinez, C. Identification of insulin-like growth factor-binding protein-1 as a potential physiological substrate for human stromelysin-3. J. Biol. Chem., 272: 25706-25712, 1997.
59. Kitagawa, Y., Ueda, M., Ando, N., Ozawa, S., Shimizu, N., and Kitajima, M. Further evidence for prognostic significance of epidermal growth factor receptor gene amplification in patients with esophageal squamous cell carcinoma. Clin. Cancer Res., 2: 909-914, 1996.
60. Furihata, M., Ishikawa, T., Inoue, A., Yoshikawa, C., Sonobe, H., Ohtsuki, Y., Araki, K., and Ogoshi, S. Determination of the prognostic significance of unscheduled cyclin A overexpression in patients with esophageal squamous cell carcinoma. Clin. Cancer Res., 2: 1781-1785, 1996.
61. Shinozaki, H., Ozawa, S., Ando, N., Tsuruta, H., Terada, M., Ueda, M., and Kitajima, M. Cyclin D1 amplification as a new predictive classification for squamous cell carcinoma of the esophagus, adding gene information. Clin. Cancer Res., 2: 1155-1161, 1996.
62. Johnson, L. D., Hunt, D. M., Kim, K., and Nachtigal, M. Amplification of stromelysin-3 transcripts from carcinomas of the colon. Hum. Pathol., 27: 964-968, 1996.